Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast

Copy/Paste the key inputs from the product brochure, per guidance from Marketing.

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia); and IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA that is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, marking the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020. The recent approval of novel oral targeted therapies—JAK inhibitors (Pfizer’s Xeljanz and AbbVie’s Rinvoq)—for ankylosing spondylitis (AS) and the impending entry of an additional IL-17 inhibitor (UCB’s bimekizumab) will further shift market dynamics.

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what key therapies are in early-phase development?
  • What are interviewed experts’ opinions on the use of Xeljanz and Rinvoq for AS? What sales / uptake could JAK inhibitors secure in AxSpA?
  • What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary research: Approximately 30 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.

Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2031, segmented by brands / generics and epidemiological subpopulations

Emerging therapies: Phase III: 1 drug; Phase II: 2 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement:

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
        • October 2021
      • Q3 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
    • Key findings
      • Market outlook
        • Key findings
          • Market share of drug classes for axial spondyloarthritis: 2020
          • Market share of drug classes for axial spondyloarthritis: 2030
          • Axial spondyloarthritis SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for axial spondyloarthritis?
          • What factors are constraining the market for axial spondyloarthritis?
        • Drug-class specific trends
          • Major-market sales of NSAIDS for axial spondyloarthritis by drug class
          • Major-market sales of TNF-alpha inhibitors for axial spondyloarthritis
          • Major-market sales of branded and biosimilar TNF-alpha inhibitors
          • Sales of TNF-alpha inhibitors for axial spondyloarthritis by market segment
          • Major-market sales of IL-17 inhibitors for axial spondyloarthritis
          • Sales of IL-17 inhibitors for axial spondyloarthritis by market segment
          • Major-market sales of JAK inhibitors for axial spondyloarthritis
          • Sales of JAK inhibitors for axial spondyloarthritis by market segment
      • Forecast
        • Market Forecast Assumptions - Axial Spondyloarthritis (2020-2030) - December 2021
        • Market Forecast Dashboards - Axial Spondyloarthritis (2020-2030) - December 2021
      • Etiology and pathophysiology
        • Disease overview
          • Classification criteria in axial spondyloarthritis
            • Systems used to classify axial spondyloarthritis
          • Presentation and disease progression
            • Key pathways and drug targets
              • Pathways involved in inflammation and bone damage in axial spondyloarthritis
          • Epidemiology
            • Key findings
              • Epidemiology populations
                • Disease definition
                • Methods
                • Sources used for total prevalent cases of axial spondyloarthritis
                • Number of total prevalent cases of axial spondyloarthritis in the major pharmaceutical markets: 2020-2030 (thousands)
                • Disease definition
                • Methods
                • Sources used for total prevalence of ankylosing spondylitis
                • Total prevalent cases of ankylosing spondylitis in the major pharmaceutical markets: 2020-2030 (thousands)
                • Disease definition
                • Methods
                • Sources used for total prevalent cases of nonradiographic axial spondyloarthritis
                • Total prevalent cases of nonradiographic axial spondyloarthritis in the major pharmaceutical markets: 2020-2030 (thousands)
                • Disease definition
                • Methods
                • Sources used for total prevalent cases of axial spondyloarthritis by HLA-B27 status
                • HLA-B27-positive cases in the major pharmaceutical markets: 2020-2030 (thousands)
                • Diagnosed prevalent cases of axial spondyloarthritis: 2020-2030 (thousands)
                • Drug-treated prevalent cases of axial spondyloarthritis: 2020-2030 (thousands)
            • Current treatment
              • Key findings
                • Treatment goals
                  • Key endpoints used in clinical trials for axial spondyloarthritis
                • Key current therapies
                  • Overview
                  • Mechanism of action of key current drug classes used for axial spondyloarthritis
                  • Current treatments used for axial spondyloarthritis
                  • Market events impacting the use of key current therapies for axial spondyloarthritis
                  • Advantages and disadvantages of NSAIDs
                  • Expert insight: NSAIDs
                  • Advantages and disadvantages of conventional DMARDs
                  • Expert insight: conventional DMARDs
                  • Advantages and disadvantages of adalimumab
                  • Expert insight: adalimumab
                  • Advantages and disadvantages of etanercept
                  • Expert insight: etanercept
                  • Advantages and disadvantages of infliximab
                  • Expert insight: infliximab
                  • Advantages and disadvantages of Simponi
                  • Expert insight: Simponi
                  • Advantages and disadvantages of Cimzia
                  • Expert insight: Cimzia
                  • Advantages and disadvantages of Cosentyx
                  • Ongoing clinical development of Cosentyx
                  • Key ongoing clinical trials of cosentyx in the treatment of axial spondyloarthritis
                  • Expert insight: Cosentyx
                  • Taltz
                  • Advantages and disadvantages of Taltz
                  • Ongoing clinical development of Taltz
                  • Key ongoing clinical trials of Taltz in the treatment of axial spondyloarthritis
                  • Expert insight: Taltz
                  • Advantages and disadvantages of Lumicef
                  • Expert insight: Lumicef
                  • Rinvoq
                  • Advantages and disadvantages of Rinvoq
                  • Ongoing clinical development of Rinvoq
                  • Key ongoing clinical trials of Rinvoq in the treatment of axSpa
                  • Expert insight: Rinvoq
                  • Advantages and disadvantages of Xeljanz
                  • Expert insight: Xeljanz
                • Medical practice
                  • Overview
                  • Factors influencing drug selection in axial spondyloarthritis
                  • Treatment decision tree for axial spondyloarthritis: United States
                  • Treatment decision tree for axial spondyloarthritis: Europe
                  • Treatment decision tree for axial spondyloarthritis:: Japan
              • Unmet need overview
                • Current and future attainment of unmet needs in axial spondyloarthritis
                • Top unmet needs in axial spondyloarthritis: current and future attainment
                • Expert insight: unmet need in axial spondyloarthritis
              • Emerging therapies
                • Key findings
                  • Key emerging therapies
                    • Key therapies in development for axial spondyloarthritis
                    • Estimated launch dates of key emerging therapies for the treatment of axial spondyloarthritis
                    • Bimekizumab profile
                    • Key ongoing clinical trials of bimekizumab in the treatment of axSpA
                    • Analysis of the clinical development program for bimekizumab
                    • Expert insight: bimekizumab
                    • Expectations for launch and sales opportunity of bimekizumab in axial spondyloarthritis
                  • Early-phase pipeline analysis
                    • Select compounds in Phase II development for axial spondyloarthritis
                • Access & reimbursement overview
                  • Region-specific reimbursement practices
                    • Key market access considerations in axial spondyloarthritis: United States
                    • General reimbursement environment: United States
                    • Key market access considerations in axial spondyloarthritis: EU5
                    • General reimbursement environment: EU5
                    • Key market access considerations in axial spondyloarthritis: Japan
                    • General reimbursement environment: Japan
                • Appendix
                  • Axial spondyloarthritis bibliography